Optimization of vasomotor and neuropsychiatric disorders treatment in climacteric syndrome

Authors

  • О. H. Horbatiuk National Pirogov Memorial Medical University, Vinnytsia, Ukraine,
  • А. P. Hryhorenko National Pirogov Memorial Medical University, Vinnytsia, Ukraine,
  • А. S. Shatkovska National Pirogov Memorial Medical University, Vinnytsia, Ukraine,
  • А. M. Binkovska National Pirogov Memorial Medical University, Vinnytsia, Ukraine,
  • V. Yu. Onyshko National Pirogov Memorial Medical University, Vinnytsia, Ukraine,
  • О. Kh. Gerich National Pirogov Memorial Medical University, Vinnytsia, Ukraine,

DOI:

https://doi.org/10.14739/2310-1210.2017.4.105110

Keywords:

climacteric, psychoneuroses, ethinylestradiol, norelgestromin

Abstract

The article presents data on a study of transdermal therapeutic system with 600 mkg ethinylestradiol and 6000 mkg norelgestromin, which was used for removal vasomotor and neuropsychiatric disorders of severe and middle course of climacteric syndrome.

Purpose: to assess the effectiveness of influence of transdermal therapeutic system with 600 mkg ethinylestradiol and 6000 mkg norelgestromin for vasomotor and neuropsychiatric disorders of severe and middle climacteric syndrome.

Materials and methods. 103 women of postmenopausal age with severe and middle climacteric disorders were under observation: 65 of them were included into the main group, 38 – the comparison group. Severity stage of climacteric manifestation was determined according to menopause rating scale (MRS) before treatment and a month after treatment. Women of the main group were offered to treat climacteric disorders with TTS, which contains 600 mkg ethinylestradiol and 6000 mkg norelgestromin, in regime 1 patch per 1 month. Traditional MHT preparation was prescribed to the women of the comparison group, this drug contains 1mg ethinylestradiol and 5 mg dydrohesteron, per os route in uninterrupted regime.

Results. It was found reduction of vegetative, vascular and neuropsychiatric menopausal symptoms and total index of menopause from 25.9 ± 1.2 to 8.2 ± 0.9 – in the main group; and from 25.4 ± 1.6 to 9.9 ± 1.2 – in the comparison group. Reliable difference (p < 0.05) was found out after treatment between indexes of the main and comparison groups according to such criteria, as: hot flashes, sleeping disorders, joint and muscle complaints, depression, anxiety. These indexes were mush better in the main group.

Conclusions. During treatment of severe and middle climacteric syndrome with TTS, which contains 600 mkg ethinylestradiol and 6000 mkg norelgestromin (Evra plaster), rapid and durable correction of vegetative, vascular and neuropsychiatric climacteric disorders was found out. Reliable reduction of total index of menopause in a month after treatment by 68.3 % from the first index (in the comparison group – 61 %) allows to recommend TTS with ethinylestradiol and norelgestromin as independent correction method for severe and middle climacteric disorders tratment.

References

Grigorenko, A. P., Shatkovskaya, A. S., Shimanskaya, O. G., & Onishko, V. Yu. (2010). Patogenez, diagnostika i lechenie osnovnykh sindromov patologicheskogo klimaksa [Pathogenesis, diagnosis and treatment of maine symptoms pathological menopause]. Medicinskie aspekty zdorov´ya zhenshchiny, 9–10(38–39), 75–77. [in Russian].

Manukhin, I. B., Tumilovich, L. G., & Gevorkyan, M. A. (2014). Ginekologicheskaya e´ndokrinologiya. Klinicheskie lekcii: rukovodstvo [Gynecological endocrinology. Clinical lecture: guideline]. Moscow: Geotar-Media. [in Russian].

Grigorenko, A. P., Gerich, O. Kh., Gorbatyuk, O. G., & Ropotan, A. H. (2011) Nemedikamentoznye metody lecheniya i fitoterapiya klimaktericheskogo sindroma [Non-drug treatments and phytotherapy of climacteric syndrome]. Reproductive endocrinology. Proceedings of the Scientific and Practical Conference “Harmoniia hormoniv – osnova zdorovia zhinky. Kyiv. [in Russian].

Horbatiuk, O. H., Shatkovska, A. S., & Hryhorenko, A. P. (patentee) (2015) Sposib korektsii klimakterychnykh porushen u zhinok perymenopauzalnoho ta postmenopauzalnoho viku [The patent for useful model №98498 Ukraine, МPК А61Р 5/00. The method of climacteric disorders correction in women of premenopausal and postmenopausal ages.]. Biulleten, 8. [in Ukrainian].

Smetnik, V. P. (2006). Medicina klimakteriya [Medicine of menopause]. Saint Petersburg: Litera. [in Russian].

de Vllliers, T., & Tatarchuk, T. F. (2016). Natsionalnyi konsensus shchodo vedennia patsiientok u klimakterii [National consensus on the management of patients in menopause]. Reproduktyvna endokrynolohiia, 1(27), 8–25. [in Ukrainian].

de Vllliers, T. J., Pines, A., Panay, N., Gambacciani, M., Archer, D. F., Baber, R. J., et al. (2013). Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric, 16, 316–337.

Shams, T., Firwana, B., Habib, F., Alshahrani, A., Alnouh, B., Murad, M. H., & Ferwana, M. (2014) SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. Journal of General Internal Medicine, 29, 204–213. doi: 10.1007/s11606-013-2535-9.

Downloads

How to Cite

1.
Horbatiuk ОH, Hryhorenko АP, Shatkovska АS, Binkovska АM, Onyshko VY, Gerich ОK. Optimization of vasomotor and neuropsychiatric disorders treatment in climacteric syndrome. Zaporozhye Medical Journal [Internet]. 2017Jul.3 [cited 2024Dec.28];(4). Available from: http://zmj.zsmu.edu.ua/article/view/105110

Issue

No. 4 (2017)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)